Glutamate clearance by astrocytes is an essential part of normal excitatory neurotransmission. Failure to adapt or maintain low levels of glutamate in the central nervous system is associated with multiple acute and chronic neurodegenerative diseases. The primary excitatory amino acid transporters in human astrocytes are EAAT1 and EAAT2 (GLAST and GLT-1, respectively, in rodents). While the inhibition of calcium/calmodulin-dependent kinase (CaMKII), a ubiquitously expressed serine/threonine protein kinase, results in diminished glutamate uptake in cultured primary rodent astrocytes (Ashpole et al. 2013) , the molecular mechanism underlying this regulation is unknown. Here, we use a heterologous expression model to explore CaMKII regulation of EAAT1 and EAAT2. In transiently transfected HEK293T cells, pharmacological inhibition of CaMKII (using KN-93 or tat-CN21) reduces [ 3 H]-glutamate uptake in EAAT1 without altering EAAT2-mediated glutamate uptake. While overexpressing the Thr287Asp mutant to enhance autonomous CaMKII activity had no effect on either EAAT1 or EAAT2-mediated glutamate uptake, over-expressing a dominantnegative version of CaMKII (Asp136Asn) diminished EAAT1 glutamate uptake. SPOTS peptide arrays and recombinant glutathione S-transferase-fusion proteins of the intracellular Nand C-termini of EAAT1 identified two potential phosphorylation sites at residues Thr26 and Thr37 in the N-terminus.
Background L-glutamate is the principal excitatory neurotransmitter in the central nervous system (Fonnum 1984) . The ability of astrocytes to rapidly and efficiently clear synaptic glutamate is integral to physiological excitatory neurotransmission (Rosenberg and Aizenman 1989; Haydon and Carmignoto 2006) . The excitatory amino acid transporters (EAAT) 1 and 2 [glutamate/aspartate transporter(GLAST) and glial glutamate transporter 1 (GLT-1) in rodents, respectively] mediate glutamate uptake by astrocytes (Pines et al. 1992; Storck et al. 1992) . However, pathological dysregulation of these transporters has been associated with elevated extracellular glutamate in the brain (Yi and Hazell 2006) , potentially contributing to neuronal dysfunction and death as a result of glutamate-induced excitotoxicity (Olney and Sharpe 1969; Choi 1992) . In fact, compromised glutamate uptake by astrocytes has been implicated in a number of different neurodegenerative diseases, including ischemic stroke, amyotrophic lateral sclerosis, traumatic brain injury, and Alzheimer's disease (Rothstein et al. 1992; Bruhn et al. 2000; van Landeghem et al. 2006; Cassano et al. 2012) . A better understanding of the complex mechanisms regulating glutamate uptake may be key to targeting the detrimental effects associated with aberrant glutamatergic neurotransmission.
The calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine protein kinase expressed in high levels in the brain, where it regulates a number of cellular processes, including calcium homeostasis, excitability, neurotransmitter synthesis/release and neuronal plasticity (Hudmon and Schulman 2002; Robison 2014) . During ischemic conditions, CaMKII initially activates, followed by rapid and persistent inactivation and aggregation (Aronowski et al. 1992; Waxham et al. 1996; Dosemeci et al. 2000; Tao-Cheng et al. 2002; Hudmon et al. 2005) . Because the neuronal death observed in animal models of cerebral ischemia correlates with the extent of CaMKII inactivation (Hanson et al. 1994) , a loss of CaMKII signaling may be an important driver of excitotoxicity (Ashpole et al. 2012b) . In fact, pharmacological inhibition of astrocytic CaMKII produces functional changes that would likely exacerbate the neurotoxic effects produced by excitotoxicity (Ashpole and Hudmon 2011; Ashpole et al. 2012b Ashpole et al. , 2013 . Specifically, CaMKII inhibition in astrocytes results in dysregulated calcium homeostasis, release of the gliotransmitter ATP and reduced glutamate uptake (Ashpole et al. 2013) ; functional changes that could compromise neuronal survival (Ashpole et al. 2013) . Astrocytes express multiple glutamate transporter subtypes (Kondo et al. 1995; Rothstein et al. 1996) . Although a recent study described regulation of a GLT-1 splice variant by CaMKII through phosphorylation of a scaffolding protein (Underhill et al. 2015) , it is unknown whether CaMKII may be functionally regulating one or both of the astrocytic glutamate transporters.
Our working hypothesis is that aberrant CaMKII activity produced by excitotoxic calcium signaling dysregulates astrocytic glutamate uptake. In order to address this question, we utilize peptide and small molecule inhibitors of CaMKII in combination with genetic manipulations via the overexpression of a dominant negative and a mutant autonomous form of CaMKII to identify mechanisms underlying EAAT regulation by CaMKII. Lastly, we explore the contribution that site-specific phosphorylation plays in the constitutive regulation of the EAAT1 transporter.
Experimental procedures
Materials Glutamic acid, glycine, polyethylenimine (PEI), poly-D-lysine (PDL) and DL-threo-b-benzyoxyaspartate (TBOA) were purchased from Sigma, St Louis, MO, USA. Vectashield Hard-Set mounting medium was obtained from Vector Laboratories (Burlingame, CA, USA) while Prolong Gold Antifade with DAPI (4 0 ,6-diamidino-2-phenylindole) 
Astrocyte cultures
Cortical astrocytes were obtained from P1 to P2 Sprague Dawley pups (male and female) as described previously (McCarthy and de Vellis 1980; Ashpole et al. 2013) according to approved Institutional Animal Care and Use Committees guidelines. Dams were obtained from Envigo (Indianapolis, IN, USA). Briefly, following enzymatic digestion and trituration, cells were resuspended in growth media [Dulbecco's modified eagle's medium (DMEM), containing 5% NuSerum, penicillin (10 units/mL), streptomycin (10 lg/mL) and B-27] and plated on PDL (50 lg/mL) coated dishes at a density of 2.5 million cells/mL. Upon reaching confluence, the plates were shaken to remove oligodendrocytes and microglia, and passaged using 0.05% trypsin (Invitrogen, Carlsbad, CA, USA).
HEK293T cell culture HEK293T cells were obtained from the American Type Culture Collection and cultured in DMEM, 10% heat inactivated fetal bovine serum, penicillin (10 units/mL), and streptomycin (10 lg/ mL) at 37°C in 5% CO 2 as previously described (Hudmon et al. 2005; Ashpole et al. 2012a) . Cells were passaged at confluency, using 0.05% trypsin (Invitrogen).
cDNA constructs cDNA for human EAAT1 and EAAT2 (obtained from Addgene in a pCMV5 backbone) was generously provided by Dr Susan Amara at the National Institute of Mental Health. Each transporter was subcloned into Creator-based acceptor vectors for mammalian expression with an N-terminal mCherry tag as previously described (Adler et al. 2013) . For glutathione S-transferase (GST)-fusion protein experiments, N-and C-termini of EAAT1 and EAAT2 and GluR1, a subunit of the a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor, were subcloned into PGEX (Plasmid gene expression) vectors, containing an N-terminal GST tag. The cDNA for human CaMKII (Ashpole et al. 2012a ) was subcloned into a Creatorbased vector with an N-terminal yellow fluorescent protein tag.
Transient transfections
For CaMKII [c-32 P]-ATP activity assays and [ 3 H]-glutamate uptake assays, HEK293T cells were transfected at 50-60% confluency with 2.5 lg cDNA and 2 mg/mL PEI in serum-free OptiMEM. Assays were performed 16-24 h later, when cells were confluent. For imaging, HEK293T cells were transfected at 70-80% confluency with 6 lg cDNA and 2 mg/mL PEI in serum-free OptiMem in 100 mm tissue culture dishes. Cells were plated onto PDL (50 lg/mL) coated glass coverslips 24 h after transfection and processed (as described below).
Microscopy
Transfected HEK293T cells (for 24-48 h) were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 for 10 min and washed 29 in cold phosphate buffered saline (PBS). Subsequently, coverslips were mounted in Vectashield Hard-Set mounting media or Prolong Gold Antifade with DAPI mounting media and fluorescence imaged in transfected cells, using a Zeiss Axio Observer Z1 (109 objective or 639 oil objective). The fluorescent images were collected and analyzed, using Axiovision 4 under differential interference contrast, red (Texas red;excit. 595 nm/ emis. 620 nm) and green channels (FITC;excit. 490 nm/emis. 525 nm).
CaMKII [c-
32 P]-ATP activity assays HEK293T cultures were washed in cold PBS, and lysed in 20 mM Tris pH 7.4, 200 mM NaCl, 0.1 mM EDTA, using a homemade protease inhibitor cocktail (1 mM AEBSF (4-benzenesulfonyl fluoride hydrochloride), 300 nM Aprotinin, 2 lM E-64, 2 lM Leupeptin) as described previously (Ashpole et al. 2013) . The lysate was sonicated briefly, vortexed, and incubated with 0.5% Triton X-100 for 5-10 min on ice. Total CaMKII activity was measured by incubating the lysate with 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 100 lM ATP, 2 mM CaCl 2 , 5 lM calmodulin, 50 lM Autocamtide-2 (AC-2) (KKALRRQETVDAL) and [c- /CaM-independent activity) was measured by incubating the lysate under similar conditions except 5 mM EGTA replaced Ca 2+ /CaM. To control for non-specific AC-2 phosphorylation in the lysate, reactions were incubated in the absence of AC-2. The linear range of the phosphorylation reactions extended > 10 min. A DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) was used to measure protein levels in the lysate using bovine serum albumin (BSA) as a standard. CaMKII activity was normalized to total protein to account for variability in cell density or lysis.
[ 3 H]-glutamate uptake assays Transfected HEK293T cells (with mCherry vector control, mCherry-EAAT1 or mCherry-EAAT2) and cultured cortical astrocytes were pretreated with pharmacological antagonists (10 lM UCPH-101, 10 lM TBOA or 10 lM DHK (dihydrokainate)) to identify the contribution of specific transporters for 20 min at 37°C. Rat physiological saline (138 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl 2 , 1.06 mM MgCl 2 , 12.4 mM HEPES, pH 7.4, 5.6 mM glucose; final pH adjusted to 7.3) containing 0.1 lCi/ml [ 3 H]-glutamate and 100 lM unlabeled glutamate was then applied to HEK293T cells for 20 min at 37°C. The cultures were then washed in cold PBS, lysed in lysis buffer (above) containing 1% Triton X-100, vortexed, incubated for 5 min on ice, diluted in 8 mL RadSafe liquid scintillation cocktail (Beckman Coulter, Brea, CA, USA) and [ 3 H] was quantified using a scintillation counter. A DC protein assay was performed as described above, and uptake was normalized to total protein.
Western blotting HEK293T cells were transfected, lysed, sonicated, and protein concentration was determined as described above. Lysate was resuspended in LDS (lithium dodecyl sulfate) sample loading buffercontaining b-mercaptoethanol and heated for 5 mins at 80°C before proteins (15-20 lg) were separated, using either a 10% Tris-Glycine gel or 4-12% Bis-Tris NuPAGE gel. Proteins were transferred onto a 0.2 lM nitrocellulose membrane and western blotting was performed, using rabbit EAAT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 1000), rabbit EAAT2 (1 : 1000; Abcam), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1 : 1000; Cell Signaling Technology, Beverly, MA, USA) antibodies, followed by a DyLight 800 -labeled secondary antibody (1 : 20 000; Licor, Lincoln, NE, USA). Antibodies are fully annotated in Table S2 . Immunostaining was quantified, using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Site-directed mutagenesis
Site-directed mutagenesis, performed as described by the manufacturer (Agilent Technologies, Santa Clara, CA, USA), was used to introduce point mutations into the human cDNAs for dCaMKII or EAAT1. Mutations and their respective primers are annotated in Table S1 . Double mutations were carried out sequentially. All mutations were verified by gene sequencing (Eurofins MWG Operon).
In vitro SPOTs phosphorylation assay 15-amino acid long peptides spanning the intracellular regions of EAAT1 and EAAT2 (1-15, 2-16, 3-17 etc.) were synthesized onto b-alanine-derivatized cellulose membranes, using the SPOTS synthesis method as described previously (Ashpole et al. 2012a; Adler et al. 2013) . Following synthesis, the membrane was de-protected twice with a solution of trifluoroacetic acid containing 5% phenol and 2% triisopropylsilane. Next, the membrane was blocked with 5% BSA in 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, and 0.02% NP-40 for 30 min followed by three washes in 100 mM Tris-HCl pH 7.4. A prereaction was performed in the presence of 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 0.5 mM CaCl 2 , 5 lM CaM, 500 lM ATP and 500 nM recombinant purified human dCaMKII for 10 min on ice to autophosphorylate dCaMKII at Thr287 as described previously (Ashpole et al. 2012a) . Membranes were subjected to a kinase phosphorylation assay in the presence of 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 0.2 mM CaCl 2 , 1 lM CaM, 0.2 mg/mL BSA, 1 mM dithiothreitol, 100 lM ATP, 6-12 lCi/ml [c-The reactions were incubated at 25°C for 4 min unless otherwise noted, terminated with three washes (100 mM sodium phosphate pH 7.0, 1 M NaCl, 10 mM EDTA) and dried as described previously (Ashpole et al. 2012a) . The extent of radioactive phosphate incorporation was quantified, using a Fujifilm (Minato, Tokyo, Japan) phosphoimager and expressed as photostimulated luminescence (PSL/mm 2 ) for a 1.5 9 1.5 mm circle, using MultiGauge (version 3.1) (Fujifilm, Minato, Tokyo, Japan).
GST-fusion protein phosphorylation GST-tagged intracellular N-and C-termini of EAAT1 and EAAT2, EAAT1 phosphorylation mutants, GluR1 and a GST vector control were expressed in BL-21 competent E. coli cells overnight at 16°C, using 0.2 mM isopropyl 1-thio-b-D-galactopyranoside. Cells were centrifuged at 200 g for 10 min, resuspended in lysis buffer (described above) and passed through a microfluidizer three times to lyse cells. A supernatant was collected after centrifugation (8000 g for 10 min) and snap-frozen for single use aliquots. GSTfusion proteins were bound to glutathione agarose in binding buffer (20 mM Tris pH 7.4, 200 mM NaCl, 1 mM EDTA, 0.1% Tween-20 containing protease inhibitor) tumbling for 1.5 h at 4°C. Beads were then washed three times in binding buffer to remove any unbound lysate. A prereaction was performed as describe above to activate and autophosphorylate human dCaMKII. GST-bound fusion proteins were then phosphorylated on the glutathione beads with 100 nM dCaMKII in reaction mix containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 0.25 mM CaCl 2 , 5 lM CaM, 10 lM ATP, and 60 lCi/ml [c-32 P]-ATP for 30 min at 25°C. The reaction was quenched with three 500 mM EDTA washes, followed by addition of LDS with b-mercaptoethanol and followed by protein denaturation at 80°C. Coomassie-blue staining of the gel allowed for visualization of GST-fusions and protein quantification, using ImageJ was used to normalize for differences in protein expression and GST-capture levels. CaMKII phosphorylation of GST fusion proteins was detected using a phosphorimager (Fujifilm) and quantified, using MultiGauge software as described above.
Statistical analysis
SigmaPlot 12.5 (San Jose, CA, USA) was used to perform statistical analysis. A one-way ANOVA followed by a post hoc Dunnett's test was used to compare differences between the means of each group. A p value of ≤ 0.05 was considered significant.
Results
As we have described previously, CN21, a potent peptide inhibitor (Vest et al. 2007 ) derived from the natural CaMKII inhibitor protein CaMKIIN (Chang et al. 1998 ) conjugated to the cell-penetrant motif, tat (Vest et al. 2010; Ashpole and Hudmon 2011) , produced a significant reduction in [ 3 H]-glutamate uptake in cultured cortical astrocytes (Fig. S1a) . Its inactive inhibitor, tat-CN21 Ala, used to verify the specificity of the active compound and off-target effects, did not alter glutamate uptake, thus recapitulating the finding that basal CaMKII signaling regulates glutamate uptake in rodent cortical astrocytes (Ashpole et al. 2013) . We next determined the pharmacological signature of the glutamate transporters responsible for uptake in our cultured astrocytes. Consistent with previous studies showing that cultured cortical astrocytes obtained from postnatal pups primarily express GLAST (the rodent homolog of EAAT1) (Gegelashvili et al. 1997; Swanson et al. 1997) , we observed that GLAST is the predominant functional glutamate transporter under our culture conditions (Fig. S1b) . While the Na + -dependent glutamate transporter inhibitor TBOA (Shimamoto et al. 2004) accounted for 82 AE 1% of the [ 3 H]-glutamate uptake under these conditions, the specific EAAT1 inhibitor UCPH-101 (Erichsen et al. 2010) reduced glutamate uptake by 75 AE 8%, whereas DHK, an EAAT2 specific inhibitor, accounted for 15 AE 8% (Fig. S1b) . Thus, because EAAT1 accounts for > 91% of the TBOA sensitive glutamate uptake, it is likely that EAAT1 is regulated by CaMKII in astrocytes. However, because CaMKII inhibition may still contribute to reduced glutamate uptake via EAAT2 in cortical astrocytes, we developed a heterologous expression system capable of exploring CaMKII regulation of both EAAT1 and EAAT2 isoforms.
Because HEK293T cell lines have been previously used as a model system to study Na + -dependent glutamate transporter regulation (Dunlop et al. 1999; Berry et al. 2005; Peacey et al. 2009 ), we transiently transfected the human astrocytic glutamate transporters EAAT1 or EAAT2 with an N-terminal mCherry fusion tag into these cells and observed similar transfection efficiencies for EAAT1 (46 AE 7%, Fig. 1a ) and EAAT2 (43 AE 9% , Fig. 1b) ; values comparable to the mCherry vector control (50 AE 5%). Western blot analysis indicates that unlike the untransfected cells, the transfected HEK293T cells produce robust EAAT1 and EAAT2 expression at the expected molecular weights for each fusion ( Fig. 1c and d) . Finally, we evaluated the function of EAAT1 and EAAT2 in our heterologous expression system by measuring [ 3 H]-glutamate uptake. When normalized to the control condition (mCherry only), ectopic expression of EAAT1 and EAAT2 produced a 3.08 AE 0.14-fold and 3.31 AE 0.32-fold increase in [ 3 H]-glutamate uptake, respectively (Fig. 1e) . These findings are consistent with a previous study that reported a 3-4 fold increase in glutamate uptake using similar conditions (Dunlop et al. 1999) . While the low basal levels of endogenous glutamate uptake in HEK293T cells are most likely because of the activity of EAAT3 (Toki et al. 1998 ), a distinct subtype of glutamate transporter predominantly localized to neurons and kidney cells (Kanai and Hediger 1992) , we confirmed that the [ 3 H]-glutamate uptake measured for EAAT1 and EAAT2 expressing cells was sensitive to the glutamate transport inhibitors UCPH-101 and TBOA as described previously (Shimamoto et al. 2004) . Comparison of the degree of pharmacological inhibition of [ 3 H]-glutamate uptake by the EAAT2-specific inhibitor, DHK (10 lM) to TBOA (10 lM) in EAAT2 transfected cells resulted in a similar level of suppression (79 AE 3% vs.
70 AE 7% respectively, data not shown), indicating that glutamate uptake in our heterologous expression system is pharmacologically regulated as expected.
We next measured the consequence of pharmacological inhibition of CaMKII on EAAT1 and EAAT2-mediated glutamate uptake. We employed two well-established CaMKII inhibitors: KN-93, a small molecule inhibitor that competes with Ca 2+ /CaM but not ATP for CaMKII activation (Sumi et al. 1991; Pellicena and Schulman 2014) , and tat-CN21. Inactive inhibitors (KN-92 and tat-CN21 Ala) were used to verify the specificity of the active compounds versus vehicle and other off-target effects. We observed a 34 AE 2% reduction in [ 3 H]-glutamate uptake for both KN-93 and tat-CN21 in EAAT1 transfected HEK293T cells compared to inactive controls KN-92 and tat-CN21 Ala (Fig. 2a  and b) . A comparable reduction in transfected EAAT1 activity was also observed in A172s, a glioblastoma cell line, following CaMKII inhibition (Fig. S1 ). Application of KN- 93 and tat-CN21 to na€ ıve HEK293T cells did not alter [ 3 H]-glutamate uptake (data not shown), indicating that any changes observed are not because of endogenous transporter activity, but rather the transfected transporter. EAAT2-mediated glutamate uptake was not altered by CaMKII inhibition (Fig. 2b) , suggesting that a general off-target effect producing reduced glutamate uptake is likely not caused by pharmacological manipulation (or vehicle itself). Thus, unlike EAAT2-mediated glutamate uptake, CaMKII inhibition selectively disrupts EAAT1 function.
Because previous work suggested dCaMKII is the predominant CaMKII isoform expressed in rodent astrocytes , we generated a mutant variant of human dCaMKII (Asp136Asn), which renders CaMKII 'dead' owing to loss of phosphotransferase activity (Chao et al. 2011) . Fluorescence imaging of yellow fluorescent protein dCaMKII with mCherry EAAT1 and EAAT2 demonstrates an overlap in expression patterns for both wild-type ( Fig. S3a and b ) and Asp136Asn dCaMKII (Fig. 3a and b) . Over-expression of Asp136Asn dCaMKII produced a 50 AE 2.9% reduction in EAAT1, but not EAAT2, mediated [
3 H]-glutamate uptake in HEK293T cells ( Fig. 3c and d) . The most likely explanation for this result is that the dead CaMKII mutant protein produces a dominant negative phenotype, as described previously for another kinase dead variant of CaMKII (Kabakov and Lisman 2015) . Thus, as an orthogonal approach to our pharmacological experiments, genetic over-expression of a dominant-negative CaMKII disrupts constitutive EAAT1 activity without influencing EAAT2 function.
Autophosphorylation of dCaMKII at Thr287 renders the kinase autonomously active and enhances CaMKII signaling independent of intracellular calcium signaling (Lai et al. 1987; Miller et al. 1988; Hudmon and Schulman 2002) . While we observed autonomously active CaMKII in our cultured HEK293T cells (21.64 AE 2.3%) as measured, using a kinase assay and the CaMKII specific substrate AC-2 (see Methods), we determined if augmenting the level of autonomous activity altered EAAT1 or EAAT2 transporter function by generating a Thr287Asp mutant. As seen previously for the catalytically dead ( Fig. 3a and b) and wild-type dCaMKII (Fig. S3a and b) , the Thr287Asp dCaMKII mutant displayed similar expression patterns in EAAT1 and EAAT2 transfected HEK293Ts (Fig. 4a and b) . Surprisingly, the over-expression of Thr287Asp dCaMKII (or wild-type dCaMKII) did not alter [ 3 H]-glutamate uptake by EAAT1 or EAAT2 ( Fig. 4c and d) , indicating that constitutive EAAT1 (or EAAT2) glutamate uptake is not further altered by enhancing autonomous CaMKII levels in HEK293T cells.
To determine if EAAT1 is a substrate of CaMKII, we generated GST-fusion proteins of the intracellular N-and C-termini of both EAAT1 and EAAT2 in bacteria and used glutathione resin to capture the transporter fusions. Purified human dCaMKII was activated in a pre-reaction to autophosphorylate Thr287 and we tested the ability of this activated CaMKII to phosphorylate fragments of the EAAT1 and EAAT2 transporter. Phosphorylation was measured by incorporation of radiolabeled phosphate into the substrates, and normalized to Coomassie-blue staining, to control for total protein used in each treatment. By pre-autophosphorylating CaMKII in non-radioactive ATP, we reduced the [c- GluR1 (Lee et al. 1998 ), a subunit of the a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor, served as a positive control (lanes 6 and 7). While we observed a weak phosphorylation signal for the N-terminus of EAAT2 (and the C-termini of EAAT1 and EAAT2), we focused on the Nterminus of EAAT1 as it was both a stronger substrate (in relation to total protein) ( Fig. 5 ) and our functional data did not uncover any defects in EAAT2 uptake following CaMKII inhibition (Figs 2 and 3) . As a complementary approach to our GST-fusion data, we tiled the intracellular regions of EAAT1, using immobilized SPOTS peptide synthesis as described previously for the voltage-gated sodium channel Nav 1.5 (Ashpole et al. 2012a) to identify if specific residues in EAAT1 were phosphorylated by dCaMKII. The EAAT1 protein (Fig. 6a) contains a sizeable N-and C-terminus, with a short first and third intracellular loop (the second loop was too short to tile). Each 15-amino acid long peptide differed by 1 amino acid, thus allowing us to test the entirety of the predicted intracellular protein sequence of EAAT1 by creating peptides 15 amino acids long differing by only one amino acid. For example, peptide 1 contains residues 1-15, peptide 2 contains residues 2-16 of the N-terminus of EAAT1 and so on (Fig. 6b) . In vitro phosphorylation was quantified, using phosphoimaging as described previously. A number of phosphorylated peptides (~peptides 18-23) in the N-terminus of EAAT1 were observed as evidenced by an increase in [c-32 P], indicative of the peptides moving through a 'hotspot' of CaMKII activity (Fig. 6c) . Visual inspection revealed two potential phospho-acceptor residues, Thr26 and Thr37. Neither the intracellular loops nor the C-terminus of EAAT1 revealed any [c-32 P] incorporation. CaMKII substrates GluR1 (Lee et al. 1998 ) and the intermediate filament protein vimentin (Inagaki et al. 2000) were included as positive controls of CaMKII phosphorylation (two bars to the far right, Fig. 6c ). Overall, these data are in agreement with the GST-fusion data (Fig. 5) , which indicated the EAAT1 N-terminus contained residues that were phosphorylated by CaMKII.
Next, we introduced Ala substitutions for the Thr26 and Thr37 residues to identify their functional contribution in the context of the GST-fusions of the EAAT1 N-terminus and tested for phosphorylation by CaMKII in vitro. Again, Ala mutants were generated for Thr26 and Thr37, as well as a double Ala mutant. In vitro CaMKII phosphorylation was carried out as previously described. Surprisingly, Thr26Ala produced a significant increase in [c-32 P] incorporation (Fig. 7) . A potential reason for this phenotype could be the enhancement of another phosphorylation site, as a result of alterations in protein folding. The Thr37Ala mutant produced a significant reduction in [c-32 P] signal compared to wildtype (53 AE 1%), suggesting that this residue is phosphorylated by CaMKII. Furthermore, the double mutant produced a reduction that was not significant (Fig. 7b , representative image in Fig. 7a ). It is plausible that the double mutant is representative of the opposing effects in [c-32 P] incorporation of the Thr26Ala mutant and the Thr37Ala mutant, thus producing a slight, but not significant decrease in [c-32 P] incorporation. However, Figure 6c suggests that Thr26 and Thr37 are potential phosphorylation sites of CaMKII. As a result of this discrepancy, we decided to measure the effect of mutations at both these residues on [ 3 H]-glutamate uptake. To identify the functional significance of the Thr26 and Thr37 phosphorylation sites on EAAT1-mediated glutamate uptake, we mutated Thr26 and Thr37 into Ala residues as single mutants and together as a double mutant in order to mimic a non-phosphorylated state. In addition to these mutants, we generated single Asp (Thr26Asp and Thr37Asp to mimic phosphorylation) and double Asp mutants to determine the contribution of both sites. Only the Thr37Ala and double mutant Thr26Ala/Thr37Ala produced a significant reduction in [ 3 H]-glutamate uptake (Fig. 8c) . Thr26
does not appear to regulate alterations in [ 3 H]-glutamate uptake mediated by EAAT1 as the Thr26Ala mutant did not produce any change in glutamate uptake. These functional changes are not due to difference in expression levels as immunoblots of HEK293T cells transfected with EAAT1 wild-type, Thr37Ala and Thr27Ala/Thr37Ala indicated that mutant variants of EAAT1 express at a similar level when compared to wild-type EAAT1 (Fig. 8a and b) . Surprisingly, neither Thr37Asp nor Thr26Asp/Thr37Asp mutants increased EAAT1-mediated glutamate uptake, suggesting that CaMKII signaling constitutively maintains the phosphorylation state of the Thr37 residue.
The functional linkage between the phosphorylation state of Thr37 and CaMKII signaling in regulating EAAT1 was evaluated by testing whether the presence of both the CaMKII inhibitor KN-93 and the Thr37Ala substitution were synergistic or additive when both manipulations were applied simultaneously. Interestingly, the Thr37Ala mutation appears to partially account (50%) for the reduction in glutamate uptake seen with pharmacological CaMKII inhibition (Fig. 8d) . Thus, the Thr37Ala mutation and the KN-93 effect are not additive, suggesting that CaMKII inhibition and mimicking the non-phosphorylation state of Thr37 may be functionally linked by a common mechanism. 
Discussion
In this study, we demonstrate that EAAT1 and EAAT2 are differentially regulated by CaMKII in HEK293T cells. We observed that pharmacological inhibition of CaMKII using both a small molecule inhibitor KN-93 and a peptide inhibitor tat-CN21 produced a~34-50% reduction in glutamate uptake mediated by EAAT1, but not EAAT2, reproducing the degree of inhibition previously observed in cortical astrocytes (Ashpole et al. 2013) . While the control small molecule KN-92 as well as the inactive tat-peptide tat-CN21-Ala did not reduce glutamate uptake, we addressed the potential for off-target effects using a completely different approach. Transfection of a catalytically dead CaMKII mutant (Asp136Asn) produced a dominant-negative phenotype and disrupted EAAT1 function, demonstrating specificity for the pharmacological and genetic manipulation of CaMKII-mediated regulation of EAAT1 function. Thus, while CaMKII activity regulates EAAT1 in our study, we did not observe CaMKII inhibition to influence EAAT2-mediated glutamate uptake.
Further, we demonstrate that EAAT1 is a novel CaMKII substrate in vitro, with an N-terminal non-consensus phosphorylation site Thr37. While inhibition of CaMKII signaling disrupts EAAT1 glutamate uptake, upregulation of CaMKII using an 'autonomous' mutant form of CaMKII (Thr287Asp, retains activity without Ca 2+ /CaM) did not alter EAAT1 function. While it is conceivable that autonomous activity is not sufficient for EAAT1 regulation, it is likely that basal CaMKII activity (21 AE 4% of maximal in HEK293 cells) is sufficient for CaMKII-mediated EAAT1 regulation in our model system.
Both SPOTS blot and GST-fusion protein data implicated Thr37 as a key residue on EAAT1 phosphorylated by CaMKII. Generation of a non-phosphorylated Thr37Ala mutant reduced EAAT1-mediated glutamate uptake in a significant manner, substantiating our in vitro findings. Our in vitro studies also proposed Thr26 as a potential CaMKII phosphorylation site, however [ 3 H]-glutamate uptake assays suggest Thr26 phosphorylation is not functionally relevant for constitutive EAAT1 activity. Overall, our data support the hypothesis that Thr37 is a CaMKII phosphorylation that is important for regulating glutamate uptake by EAAT1. Interestingly, the Thr37 residue we identified on EAAT1 is not conserved in EAAT2, potentially explaining why we did not observe CaMKII to regulate EAAT2. Because the nonphosphorylated Thr37Ala mutation did not reduce EAAT1 function to the level seen with pharmacological or genetic CaMKII inhibition, we conclude that our experimental paradigm may have failed to uncover either additional phosphorylation sites and/or an alternative mechanism contributes to EAAT1 regulation. However, it is important to note that while Thr37Ala mutation in EAAT1 does not produce the same level of glutamate transporter inhibition as seen following CaMKII inhibition, the Thr37Ala mutation is not synergistic or additive with KN-93 treatment, consistent with a shared mechanism linking the Thr37Ala mutant and reduced CaMKII signaling.
Interestingly, a number of reports suggest that GLAST (EAAT1) is the primary astrocytic glutamate transporter in dissociated rodent cultures, with GLT-1 (EAAT2) being expressed at much lower levels (Gegelashvili et al. 1997; Swanson et al. 1997) , a finding that is substantiated in this manuscript. We find that the degree of reduction in glutamate uptake elicited by inhibiting CaMKII is consistent for both EAAT1 transfected HEK293Ts and cortical astrocytic cultures, further supporting the notion that GLAST (EAAT1) is the predominant transporter expressed in astrocytic cultures. Our finding that EAAT1 is positively regulated by CaMKII signaling and that EAAT1 itself is a CaMKII substrate is a novel discovery. The only splice variant of EAAT1 described to date in humans is EAAT1ex9skip (named so since it lacks the entirety of exon 9), and it contains the Thr37 residue our study implicates as being phosphorylated by CaMKII (Vallejo-Illarramendi et al. 2005) . This splice variant lacks functional glutamate uptake activity and localizes to the endoplasmic reticulum as a truncated protein, where it instead serves as a dominant-negative over full-length EAAT1. Future studies are needed to determine what the functional consequence of CaMKII phosphorylation of Thr37 on EAAT1ex9skip might be. In addition, it will be beneficial to examine the specific contribution of Thr37 phosphorylation on glutamate uptake within native astrocytes in future studies. We mechanistically dissected the regulation of this individual residue within the EAAT1 transporter, using a heterologous expression system. While HEK293T cells are ideal to explore functional studies in transporter isoforms and mutant variants, future studies performed within astrocytes must be carefully designed and controlled to account for contaminating endogenous EAAT1 or EAAT2 expression.
Recent work from the Amara laboratory shows that CaMKII signaling alters trafficking of EAAT2b, a splice variant of EAAT2 with alterations at the C-terminus (Underhill et al. 2015) . In this study CaMKII signaling appears to be working through a scaffolding protein that negatively regulates EAAT2b trafficking (Underhill et al. 2015) . Specifically, CaMKII phosphorylation of Discs large homolog 1 (DLG1/SAP97), decreases surface expression of EAAT2b and presumably transporter activity. This effect was isoform specific, as EAAT2a trafficking was not affected by CaMKII signaling. Our study confirms that EAAT2a is not altered by CaMKII signaling and extends this work by showing that CaMKII can produce isoform specific modulation of EAAT activity. The idea that a kinase can differentially regulate subtypes of transporters is not unprecedented. For example, glycogen synthase kinase 3b has been shown to differentially modulate GLAST and GLT-1, producing a down-regulation in GLAST but up-regulation in GLT-1 activity and cell-surface expression via phosphorylation of the transporters (Jimenez et al. 2014) . Future studies are required to determine how basal regulation of EAAT1 by CaMKII is coupled to EAAT2b function. Collectively, glutamate transporter regulation by CaMKII appears complex in that it can have opposing outcomes on transporter function that are isoform dependent.
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